Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 20.6 CHF -1.2% Market Closed
Market Cap: 774m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Intrinsic Value

KURN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one KURN stock under the Base Case scenario is 5.96 CHF. Compared to the current market price of 20.6 CHF, Kuros Biosciences AG is Overvalued by 71%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

KURN Intrinsic Value
5.96 CHF
Overvaluation 71%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Kuros Biosciences AG

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for KURN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about KURN?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Kuros Biosciences AG

Provide an overview of the primary business activities
of Kuros Biosciences AG.

What unique competitive advantages
does Kuros Biosciences AG hold over its rivals?

What risks and challenges
does Kuros Biosciences AG face in the near future?

Has there been any significant insider trading activity
in Kuros Biosciences AG recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kuros Biosciences AG.

Provide P/S
for Kuros Biosciences AG.

Provide P/E
for Kuros Biosciences AG.

Provide P/OCF
for Kuros Biosciences AG.

Provide P/FCFE
for Kuros Biosciences AG.

Provide P/B
for Kuros Biosciences AG.

Provide EV/S
for Kuros Biosciences AG.

Provide EV/GP
for Kuros Biosciences AG.

Provide EV/EBITDA
for Kuros Biosciences AG.

Provide EV/EBIT
for Kuros Biosciences AG.

Provide EV/OCF
for Kuros Biosciences AG.

Provide EV/FCFF
for Kuros Biosciences AG.

Provide EV/IC
for Kuros Biosciences AG.

Show me price targets
for Kuros Biosciences AG made by professional analysts.

What are the Revenue projections
for Kuros Biosciences AG?

How accurate were the past Revenue estimates
for Kuros Biosciences AG?

What are the Net Income projections
for Kuros Biosciences AG?

How accurate were the past Net Income estimates
for Kuros Biosciences AG?

What are the EPS projections
for Kuros Biosciences AG?

How accurate were the past EPS estimates
for Kuros Biosciences AG?

What are the EBIT projections
for Kuros Biosciences AG?

How accurate were the past EBIT estimates
for Kuros Biosciences AG?

Compare the revenue forecasts
for Kuros Biosciences AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kuros Biosciences AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kuros Biosciences AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kuros Biosciences AG compared to its peers.

Compare the P/E ratios
of Kuros Biosciences AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Kuros Biosciences AG with its peers.

Analyze the financial leverage
of Kuros Biosciences AG compared to its main competitors.

Show all profitability ratios
for Kuros Biosciences AG.

Provide ROE
for Kuros Biosciences AG.

Provide ROA
for Kuros Biosciences AG.

Provide ROIC
for Kuros Biosciences AG.

Provide ROCE
for Kuros Biosciences AG.

Provide Gross Margin
for Kuros Biosciences AG.

Provide Operating Margin
for Kuros Biosciences AG.

Provide Net Margin
for Kuros Biosciences AG.

Provide FCF Margin
for Kuros Biosciences AG.

Show all solvency ratios
for Kuros Biosciences AG.

Provide D/E Ratio
for Kuros Biosciences AG.

Provide D/A Ratio
for Kuros Biosciences AG.

Provide Interest Coverage Ratio
for Kuros Biosciences AG.

Provide Altman Z-Score Ratio
for Kuros Biosciences AG.

Provide Quick Ratio
for Kuros Biosciences AG.

Provide Current Ratio
for Kuros Biosciences AG.

Provide Cash Ratio
for Kuros Biosciences AG.

What is the historical Revenue growth
over the last 5 years for Kuros Biosciences AG?

What is the historical Net Income growth
over the last 5 years for Kuros Biosciences AG?

What is the current Free Cash Flow
of Kuros Biosciences AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kuros Biosciences AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Kuros Biosciences AG

Current Assets 33.2m
Cash & Short-Term Investments 13.7m
Receivables 11m
Other Current Assets 8.5m
Non-Current Assets 44.1m
PP&E 2.9m
Intangibles 40.9m
Other Non-Current Assets 209k
Current Liabilities 12.2m
Accounts Payable 2.8m
Accrued Liabilities 8.7m
Other Current Liabilities 605k
Non-Current Liabilities 5m
Long-Term Debt 5m
Efficiency

Earnings Waterfall
Kuros Biosciences AG

Revenue
52.5m CHF
Cost of Revenue
-11m CHF
Gross Profit
41.6m CHF
Operating Expenses
-50.8m CHF
Operating Income
-9.2m CHF
Other Expenses
336k CHF
Net Income
-8.9m CHF

Free Cash Flow Analysis
Kuros Biosciences AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

KURN Profitability Score
Profitability Due Diligence

Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
Declining ROE
32/100
Profitability
Score

Kuros Biosciences AG's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

KURN Solvency Score
Solvency Due Diligence

Kuros Biosciences AG's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Negative Net Debt
69/100
Solvency
Score

Kuros Biosciences AG's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KURN Price Targets Summary
Kuros Biosciences AG

There are no price targets for KURN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for KURN?

Click here to dive deeper.

Dividends

Kuros Biosciences AG
does not pay dividends
Shareholder Yield

Current shareholder yield for KURN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

KURN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Kuros Biosciences AG Logo
Kuros Biosciences AG

Country

Switzerland

Industry

Biotechnology

Market Cap

757.4m CHF

Dividend Yield

0%

Description

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

Contact

ZUERICH
Schlieren
Wagistrasse 25
+41447334747.0
www.kuros.ch

IPO

2002-10-29 00:00:00

Employees

58

Officers

CEO & Director
Mr. Christopher T. Fair
Chief Financial Officer
Mr. Daniel Geiger
COO & GM of BV
Mr. Sjoerd Musters
President of Innovation and Strategy & Executive Director
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.
Senior Vice President of Marketing & Business Development
Mr. G. Joseph Ross
Vice President of Global Human Resources
Ms. Nikki Coleman
Show More
Chief Development Officer
Dr. Philippe Saudan Ph.D.
Chief Commercial Officer
Mr. John Griffin
Senior Vice President of Medical & Clinical Affairs
Dr. Katherine Sage D.O., FAAOS, M.S.
Consultant
Dr. Virginia Jamieson
Show Less

See Also

Discover More
What is the Intrinsic Value of one KURN stock?

The intrinsic value of one KURN stock under the Base Case scenario is 5.96 CHF.

Is KURN stock undervalued or overvalued?

Compared to the current market price of 20.6 CHF, Kuros Biosciences AG is Overvalued by 71%.

Back to Top